Rheumatoid Arthritis Forecast in 17 Major Markets 2016 with 10-Year Forecast Snapshot

Dublin, Oct. 12, 2016 -- Research and Markets has announced the addition of the "Rheumatoid Arthritis Forecast in 17 Major Markets 2016-2026" report to their offering.

Rheumatoid arthritis (RA) is classified as an autoimmune disease and occurs when the immune system attacks the synovium (membranes surrounding joints). The inflammation resulting from the attack causes thickening of the synovium, which eventually destroys the cartilage and bone within the joint. The tendons and ligaments holding the joint together weaken and stretch, resulting in gradual loss of joint shape and alignment.

The prevalence of RA has been rumoured to be in decline over the past 20-30 years, although there is nothing concrete in the literature to substantiate if this is actually the case.

This report provides the current prevalent population for Rheumatoid Arthritis across 17 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, NL, Denmark, Norway, Greece, Turkey, Brazil, Mexico, Argentina, Japan and India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of Rheumatoid Arthritis have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

The following are considered features or comorbid conditions associated with RA:

• Smoking
• Obesity
• Diabetes
• Metabolic syndrome
• Hypertension
• Extra-articular manifestations
• Erosive disease
• Cachexia (muscle wasting)

Key Topics Covered:

1. Introduction
2. Cause of the Disease
3. Risk Factors & Prevention
4. Diagnosis of the Disease
5. Variation by Geography/Ethnicity
6. Disease Prognosis & Clinical Course
7. Key Co-morbid Conditions associated with the Disease
8. Methodology for Quantification of Patient Numbers
9. Top-Line Prevalence for Rheumatoid Arthritis
10. Clinical Features of RA Patients
11. Comorbidities and Biomarkers of RA Patients
12. RA Patients treated by Rheumatologists
13. Abbreviations and Acronyms used in the Report
14. Patient-Based Offering
15. Online Pricing Data and Platforms
16. References
17. Appendix

For more information about this report visit http://www.researchandmarkets.com/research/b44rz3/rheumatoid

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Immune Disorders Drugs, Musculoskeletal Disorders Drugs